Biomaterials of different sizes for enhanced adoptive cell transfer therapy in solid tumors.
10.3724/zdxbyxb-2024-0651
- Author:
Jiaxin CHEN
1
;
Rui LIU
2
;
Yingqi TANG
2
;
Chenggen QIAN
3
Author Information
1. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, State Key Laboratory of Natural Medicines, Nanjing 210009, China. 328465357@qq.com.
2. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, State Key Laboratory of Natural Medicines, Nanjing 210009, China.
3. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, State Key Laboratory of Natural Medicines, Nanjing 210009, China. cgqian@cpu.edu.cn.
- Publication Type:English Abstract
- Keywords:
Adoptive cell transfer;
Biomaterials;
Chimeric antigen receptor T cell therapy;
Drug delivery;
Immune cells;
Review;
Tumor microenvironment
- MeSH:
Humans;
Neoplasms/therapy*;
Biocompatible Materials/chemistry*;
Immunotherapy, Adoptive/methods*;
Nanoparticles;
Hydrogels;
Adoptive Transfer/methods*;
Animals
- From:
Journal of Zhejiang University. Medical sciences
2025;54(4):469-478
- CountryChina
- Language:Chinese
-
Abstract:
Adoptive cell transfer (ACT) shows significant efficacy against hema-tological malignancies but is limited in solid tumors due to poor homing, immunosuppre-ssion, and potential toxicity. Biomaterials spanning from nano- to macroscales-including nanoparticles, microspheres/micropatches, and hydrogels-offer unique advantages for ex vivo cell engineering, in vivo delivery, and modulation of the tumor microenvironment. Specifically, nanoparticles enable gene delivery, artificial antigen-presenting cell engi-neering, and immune microenvironment remodeling. Microspheres/micropatches improve immune cell expansion, targeted activation, and localized retention. Hydrogels enhance ACT via in situ genetic engineering, 3D culture support, and cytokine co-delivery. This review summarizes advances in biomaterial-enhanced ACT, highlighting their potential to improve delivery efficiency, amplify antitumor responses, and reduce toxicity. These insights may accelerate the clinical translation of ACT for solid tumors.
